Characterization and molecular detection of atherothrombosis by magnetic resonance - Potential tools for individual risk assessment and diagnostics

Annals of Medicine

Volumn 38, Issue 5, 2006, Pages 322-336

  Ala Korpela, Mika ^a   Sipola, Petri ^b   Kaski, Kimmo ^a  

^a AALTO UNIVERSITY   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Atherosclerosis; Magnetic resonance imaging; Magnetic resonance spectroscopy; Molecular diagnostic techniques; Molecular probe techniques; Thrombosis

Indexed keywords

ATORVASTATIN; FIBRIN; FLUOROCARBON; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; HIGH DENSITY LIPOPROTEIN; IRON OXIDE; LIPOPROTEIN; NANOPARTICLE; STATIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANGIOGRAPHY; ATHEROSCLEROSIS; BODY FLUID; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; EX VIVO STUDY; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MACROPHAGE; METHODOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SCREENING; THROMBOSIS; TOMOGRAPHY; X RAY;

ANIMALS; ATHEROSCLEROSIS; CONTRAST MEDIA; FERRIC COMPOUNDS; FIBRIN; FLUOROCARBONS; HUMANS; INTEGRIN ALPHAVBETA3; LIPOPROTEINS; LIPOPROTEINS, HDL; MACROPHAGES; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; RISK FACTORS; THROMBOSIS;

EID: 33748650593     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890600862418     Document Type: Review

References (74)

1. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Disc. 2004;3:913-25.
2. Pentikäinen MO, Öörni K, Ala-Korpela M, Kovanen PT. Modified LDL-trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med. 2000;247:359-70.
3. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque. Part I: Evolving concepts. J Am Coll Cardiol. 2005;46:937-54.
4. Opie LH, Commerford PJ, Gersh BJ. Controversies in stable coronary artery disease. Lancet. 2006;367:69-78.
5. Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation. 2005;111:3465-72.
6. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664-72.
7. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003;108:1772-8.
8. Fuster V. Editorial: The evolving role of CT and MRI in atherothrombotic evaluation and management. Nat Clin Pract Cardiovasc Med. 2005;2:323.
9. Kim WY, Danias PG, Stuber M, Flamm SD, Plein S, Nagel E, et al. Coronary magnetic resonance angiography for the detection of coronary stenoses. N Engl J Med. 2001;345:1863-9.
10. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-5.
11. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157-66.
12. Lipinski MJ, Fuster V, Fisher EA, Fayad ZA. Technology insight: targeting of biological molecules for evaluation of high-risk atherosclerotic plaques with magnetic resonance imaging. Nat Clin Pract Cardiovasc Med. 2004;1:48-55.
13. Winslow RD, Mehta D, Fuster V. Sudden cardiac death: mechanisms, therapies and challenges. Nat Clin Pract Cardiovasc Med. 2005;2:352-60.
14. Raggi P, Taylor A, Fayad Z, O'Leary D, Nissen S, Rader D, et al. Atherosclerotic plaque imaging: contemporary role in preventive cardiology. Arch Intern Med. 2005;165:2345-53.
15. 1H NMR spectroscopy of human blood plasma. Progr Nucl Magn Reson Spectr. 1995;27:475-554.
16. Lardo AC, Fayad ZA, Chronos NAF, Fuster V, editors. Cardiovascular magnetic resonance. Established and emerging applications. London, New York: Martin Dunitz; 2003.
17. Nagel E, van Rossum AC, Fleck E, editors. Cardiovascular magnetic resonance. Darmstadt: Steinkopff Verlag; 2004.
18. Mollet NR, Cademartiri F, van Mieghem CA, Runza G, McFadden EP, Baks T, et al. High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation. 2005;112:2318-23.
19. Sakuma H, Ichikawa Y, Suzawa N, Hirano T, Makino K, Koyama N, et al. Assessment of coronary arteries with total study time of less than 30 minutes by using whole-heart coronary MR angiography. Radiology. 2005;237:316-21.
20. Fuster V, Fayad ZA, Moreno PR, Poon M, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque. Part II: Approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol. 2005;46:1209-18.
21. Itskovich VV, Samber DD, Mani V, Aguinaldo JG, Fallon JT, Tang CY, et al. Quantification of human atherosclerotic plaques using spatially enhanced cluster analysis of multicontrast-weighted magnetic resonance images. Magn Reson Med. 2004;52:515-23.
22. Cappendijk VC, Cleutjens KB, Kessels AG, Heeneman S, Schurink GW, Welten RJ, et al. Assessment of human atherosclerotic carotid plaque components with multisequence MR imaging: initial experience. Radiology. 2005;234:487-92.
23. Viereck J, Ruberg FL, Qiao Y, Perez AS, Detwiller K, Johnstone M, et al. MRI of atherothrombosis associated with plaque rupture. Arterioscler Thromb Vasc Biol. 2005;25:240-5.
24. Choudhury RP, Aguinaldo JG, Rong JX, Kulak JL, Kulak AR, Reis ED, et al. Atherosclerotic lesions in genetically modified mice quantified in vivo by non-invasive high-resolution magnetic resonance microscopy. Atherosclerosis. 2002;162:315-21.
25. McAteer MA, Schneider JE, Clarke K, Neubauer S, Channon KM, Choudhury RP. Quantification and 3D reconstruction of atherosclerotic plaque components in apolipoprotein E knockout mice using ex vivo high-resolution MRI. Arterioscler Thromb Vasc Biol. 2004;24:2384-90.
26. Fayad ZA, Fuster V, Fallon JT, Jayasundera T, Worthley SG, Helft G, et al. Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation. 2000;102:506-10.
27. Kim WY, Stuber M, Bornert P, Kissinger KV, Manning WJ, Botnar RM. Three-dimensional black-blood cardiac magnetic resonance coronary vessel wall imaging detects positive arterial remodeling in patients with nonsignificant coronary artery disease. Circulation. 2002;106:296-9.
28. Jaffer FA, O'Donnell CJ, Larson MG, Chan SK, Kissinger KV, Kupka MJ, et al. Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002;22:849-54.
29. Wiesmann F, Petersen SE, Leeson PM, Francis JM, Robson MD, Wang Q, et al. Global impairment of brachial, carotid, and aortic vascular function in young smokers: direct quantification by high-resolution magnetic resonance imaging. J Am Coll Cardiol. 2004;44:2056-64.
30. Yuan C, Zhang SX, Polissar NL, Echelard D, Ortiz G, Davis JW, et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation. 2002;105:181-5.
31. European Carotid Surgery Trialists' Collaborative Group, Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet. 1998;351:1379-87.
32. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions. Two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation. 2002;106:2884-7.
33. Yonemura A, Momiyama Y, Fayad ZA, Ayaori M, Ohmori R, Higashi K, et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol. 2005;45:733-42.
34. Taniguchi H, Momiyama Y, Fayad ZA, Ohmori R, Ashida K, Kihara T, et al. In vivo magnetic resonance evaluation of associations between aortic atherosclerosis and both risk factors and coronary artery disease in patients referred for coronary angiography. Am Heart J. 2004;148:137-43.
35. Hegyi L, Hockings PD, Benson MG, Busza AL, Overend P, Grimsditch DC, et al. Short term arterial remodelling in the aortae of cholesterol fed New Zealand white rabbits shown in vivo by high-resolution magnetic resonance imaging-implications for human pathology. Pathol Oncol Res. 2004;10:159-65.
36. Viles-Gonzalez JF, Fuster V, Corti R, Valdiviezo C, Hutter R, Corda S, et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition-a magnetic resonance imaging study. Eur Heart J. 2005;26:1557-61.
37. Choudhury RP, Fuster V, Badimon JJ, Fisher EA, Fayad ZA. MRI and characterization of atherosclerotic plaque emerging applications and molecular imaging. Arterioscler Thromb Vasc Biol. 2002;22:1065-74.
38. Lombardi M, Aquaro G, Favilli B. Contrast media in cardiovascular magnetic resonance. Curr Pharm Des. 2005;11:2151-61.
39. Kramer CM, Cerilli LA, Hagspiel K, DiMaria JM, Epstein FH, Kern JA. Magnetic resonance imaging identifies the fibrous cap in atherosclerotic abdominal aortic aneurysm. Circulation. 2004;109:1016-21.
40. Yuan C, Kerwin WS, Ferguson MS, Polissar N, Zhang S, Cai J, et al. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J Magn Reson Imaging. 2002;15:62-7.
41. Barkhausen J, Ebert W, Heyer C, Debatin JF, Weinmann HJ. Detection of atherosclerotic plaque with Gadofluorine-enhanced magnetic resonance imaging. Circulation. 2003;108:605-9.
42. Sirol M, Itskovich VV, Mani V, Aguinaldo JGS, Fallon JT, Misselwitz B, et al. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation. 2004;109:2890-6.
43. Cai J, Hatsukami TS, Ferguson MS, Kerwin WS, Saam T, Chu B, et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque. Comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation. 2005;112:3437-44.
44. Lanza GM, Winter PM, Caruthers SD, Morawski AM, Schmieder AH, Crowder KC, et al. Magnetic resonance molecular imaging with nanoparticles. J Nucl Cardiol. 2004;11:733-43.
45. 3-integrin-targeted nanoparticles. Circulation. 2003;108:2270-4.
46. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001;103:415-22.
47. Colley CS, Kazarian SG, Weinberg PD, Lever MJ. Spectroscopic imaging of arteries and atherosclerotic plaques. Biopolymers. 2004;74:328-35.
48. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003;107:2453-8.
49. Cyrus T, Winter PM, Caruthers SD, Wickline SA, Lanza GM. Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Rev Cardiovasc Ther. 2005;3:705-15.
50. Schmitz SA, Taupitz M, Wagner S, Wolf KJ, Beyersdorff D, Hamm B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging. 2001;14:355-61.
51. Trivedi RA, U-King-Im JM, Graves MJ, Cross JJ, Horsley J, Goddard MJ, et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke. 2004;35:1631-5.
52. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc. 2004;126:16316-7.
53. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation. 2001;104:1280-5.
54. Botnar RM, Perez AS, Witte S, Wiethoff AJ, Laredo J, Hamilton J, et al. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation. 2004;109:2023-9.
55. Sirol M, Aguinaldo JG, Graham PB, Weisskoff R, Lauffer R, Mizsei G, et al. Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. Atherosclerosis. 2005;182:79-85.
56. Botnar RM, Buecker A, Wiethoff AJ, Parsons EC Jr, Katoh M, Katsimaglis G, et al. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation. 2004;110:1463-6.
57. Sirol M, Fuster V, Badimon JJ, Fallon JT, Moreno PR, Toussaint JF, et al. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation. 2005;112:1594-600.
58. 19F nanoparticles. Magn Reson Med. 2004;52:1255-62.
59. Wickline SA, Neubauer AM, Winter P, Caruthers S, Lanza G. Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol. 2006;26:435-41.
60. Jaffer FA, Weissleder R. Seeing within: molecular imaging of the cardiovascular system. Circ Res. 2004;94:433-45.
61. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 1992;38:1632-8.
62. 1H NMR-based absolute quantitation of human lipoproteins and their lipid contents directly from plasma. J Lipid Res. 1994;35:2292-304.
63. Bathen TF, Krane J, Engan T, Bjerve KS, Axelson D. Quantification of plasma lipids and apolipoproteins by use of proton NMR spectroscopy, multivariate and neural network analysis. NMR Biomed. 2000;13:271-88.
64. 1H-NMR-based metabonomics. Nat Med. 2002;8:1439-44.
65. Everett CJ, Mainous AG 3rd, Koopman RJ, Diaz VA. Predicting coronary heart disease risk using multiple lipid measures. Am J Cardiol. 2005;95:986-8.
66. Toussaint JF, Pachot-Clouard M, Kantor HL. Tissue characterization of atherosclerotic plaque vulnerability by nuclear magnetic resonance. J Cardiovasc Magn Reson. 2000;2:225-32.
67. 13C-NMR. Arterioscler Thromb Vasc Biol. 2000;20:2682-8.
68. 13C-NMR spectroscopy of human atherosclerotic lesions. Relation between fatty acid saturation, cholesteryl ester content, and luminal obstruction. Arterioscler Thromb. 1994;14:1951-7.
69. Stoneman VE, Bennett MR. Role of apoptosis in atherosclerosis and its therapeutic implications. Clin Sci (Lond). 2004;107:343-54.
70. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat Med. 1999;5:1323-7.
71. Trouard TP, Altbach MI, Hunter GC, Eskelson CD, Gmitro AF. MRI and NMR spectroscopy of the lipids of atherosclerotic plaque in rabbits and humans. Magn Reson Med. 1997;38:19-26.
72. Öörni K, Posio P, Ala-Korpela M, Jauhiainen M, Kovanen PT. Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans. Arterioscler Thromb Vasc Biol. 2005;25:1678-83.
73. Ruberg FL, Viereck J, Phinikaridou A, Qiao Y, Loscalzo J, Hamilton JA. Identification of cholesteryl esters in human carotid atherosclerosis by ex vivo image-guided proton magnetic resonance spectroscopy. J Lipid Res. 2006;47:310-7.
74. Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D'Ambrosia G, Arbique D, Vongpatanasin W, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003;49:417-23.